Abstract
Acute myelogenous leukemias (AMLs)are aggressive hematological neoplasms that require,in most cases,urgent treatment.Despite intensive treatment with cytostatic drugs,only a minority of patients can be cured at present.In adults,about 80%of all acute leukemias belong to the group of AML.The term “acute nonlymphocytic leukemia ” is often used interchangeably for AML.The incidence of AML is about three to four new cases per 100,000 persons.AML is rare in children and young adults;the incidence of AML increases with advancing age,the median age being between 60 and 70 yr.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after highdose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.
Burnett AK, Eden OB. The treatment of acute leukaemia. Lancet 1997;349:270–275.
Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of the MRC AML10 trial. Lancet 1998;351:700–708.
Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol 1997;24:32–44.
Cassileth PA, Strout MP, Gilliland DG. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in remission. N Engl J Med 1998;339:1649–1656.
Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997;24:92–102.
Marcucci G, MrÓzek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Op Hematol 2005; 12:68–75.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896–903.
Stock W, Thirman MJ. Pathobiology of acute myeloid leukemia. UpToDate® Version 14.2 (June 2006)(http://utdol.com).
Stone RM, O’Donnell M, Sekeres MA. Acute myeloid leukemia. Hematology 2004: American Society of Hematolology Education Program Book. Washington, DC: American Society of Hematology, 2004:98–117.
Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021–1028.
Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute myeloid leukemia. Blood 2005;106:2243.
Valk PJM, Delwel R, Löwenberg B: Gene expression profiling in acute myeloid leukemia. Current Op Hematol 2005;12:76–81.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Munker, R. (2007). Acute Myelogenous Leukemias. In: Munker, R., Hiller, E., Glass, J., Paquette, R. (eds) Modern Hematology. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-149-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-149-9_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-557-6
Online ISBN: 978-1-59745-149-9
eBook Packages: MedicineMedicine (R0)